据悉，米美欣是当前唯一一款在国内获批上市、具有高技术壁垒的国产羟考酮纳洛酮缓释片。公司相信，米美欣解决了当前的临床需求，在中国具备良好的市场潜力。同时，该产品可与集团的抗肿瘤产品形成丰富的产品组合，并协同肿瘤领域现有的资源与优势，加速推动公司在该领域布局和发展。Luye Pharma (02186) has risen nearly 3%. As of press time, it has risen 2.84% to HKD 2.9, with a turnover of HKD 3.9259 million.
According to the Zhitong Finance and Economics APP, Luye Pharma (02186) has risen nearly 3%. As of press time, it has risen 2.84% to HKD 2.9, with a turnover of HKD 3.9259 million.
On the news front, Luye Pharma announced that its new pain relief product, Mimi Xin (Hydrocodone-Naloxone Sustained-Release Tablets, LY021702) in the analgesic field, has received approval for marketing from the China National Medical Products Administration on June 28, 2024 and is suitable for severe pain (cancer and non-cancer pain) in adults who need opioid analgesics to fully control it.
It is reported that Mimi Xin is currently the only domestically produced hydrocodone-naloxone sustained-release tablets approved for marketing in China, with high technological barriers. The company believes that Mimi Xin addresses current clinical needs and has good market potential in China. At the same time, this product can form a rich product combination with the company's anti-tumor products, and synergize with existing resources and advantages in the tumor field, accelerating the company's layout and development in this area.
